{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-25-000005","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.950457+00:00","generated_at":"2026-05-27T03:42:15.808148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)","bullets":["Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).","GAAP EPS $1.16 vs $1.42; FY $7.56 vs $12.49, driven by mark-to-market losses on equity investments.","Non-GAAP EPS $5.31 vs $4.71; FY $19.84 vs $18.65, driven by higher revenues offset by higher expenses.","Full-year free cash flow $10.4B vs $7.4B in 2023, driven by business performance and working capital timing.","21 products achieved record full-year sales; rare disease sales $1.2B in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-25-000005","json":"https://secwatch.observer/filing/0000318154-25-000005.json","markdown":"https://secwatch.observer/filing/0000318154-25-000005.md","text":"https://secwatch.observer/filing/0000318154-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/0000318154-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:42:15.808148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}